Crispr Therapeutics AG vs Norfolk Southern Corporation — how do they compare? Crispr Therapeutics AG trades at $53.97 (market cap $5.23B), while Norfolk Southern Corporation trades at $335.07 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 14.4× Crispr Therapeutics AG's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NSC | |
|---|---|---|
Market Cap | $5.23B | $75.15B |
Sector | Health | Technology |
52-Week High | $76.78 | $350.66 |
52-Week Low | $44.34 | $272.35 |
Enterprise Value | $3.65B | $90.70B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Norfolk Southern (NSC) trades at $334.44, up 0.15% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including three consecutive quarterly earnings beats, a net income margin of 21.02%, and robust cash flow from operations of $4.36B in 2025. Recent news highlights merger developments with Union Pacific and positive Q2 2026 results driven by freight demand.
Outlook is positive with a consensus price target of $369.67, implying upside, but risks include high valuation (P/E 28.55), merger regulatory scrutiny, and fuel cost pressures. Institutional sentiment is mixed with 43.75% buy ratings, yet hedge fund activity suggests potential momentum.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →